Optiver Holding
DSGN icon

Optiver Holding’s Design Therapeutics DSGN Stock Holding History

Optiver Holding’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.38K Sell
224
-104
-32% -$1.05K ﹤0.01% 1773
2025
Q4 		$3.08K Hold
328
– – ﹤0.01% 1737
2025
Q3 		$2.47K Buy
+328
New +$1.64K ﹤0.01% 2295

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Optiver Holding's DSGN Position: Q1 2026 in Review

Optiver Holding reduced its Design Therapeutics (DSGN) stake by 32% in Q1 2026, selling an estimated $1.05K and leaving 224 shares worth $2.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

Optiver Holding first reported a position in DSGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.08K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Optiver Holding held 224 shares of Design Therapeutics worth $2.38K as of Q1 2026.
  • Optiver Holding sold 104 Design Therapeutics shares in Q1 2026, an estimated $1.05K.
  • Design Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1773 holding.
  • Optiver Holding first reported a position in Design Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Design Therapeutics position peaked at $3.08K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.